Anti-Bcl-2 (Phospho-Thr56) Antibody (43064)

Peptide sequence that includes phosphorylation site of threonine 56 (G-H-T(p)-P-H) derived from human Bcl-2 and conjugated to KLH.

PBS (without Mg2 and Ca2 ), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Liquid

Affinity-purified on phosphopeptide; non-phosphopeptidereactive antibodies were removed by chromatography on non-phosphorylated peptide

This antibody is stable for at least one (1) year at -20°C.

Next Day 2-8°C

Rabbit Polyclonal Antibody specific to Bcl-2 (Phospho-Thr56)

Bcl-2 protein suppresses apoptosis in a variety of cellular systems including factor-dependent lymphohematopoietic and neural cells. It regulates cell death by controlling the mitochondrial membrane permeability and appears to function in a feedback loop system with caspase. Bcl-2 inhibits caspase acativity either by preventing release of cytochrome c from the mitochondria and/or by binding to apoptosis-activating factor (Apaf-1). The predicted molecular weight of Bcl-2 is ~26kDa.

Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells (PubMed:1508712, PubMed:8183370). Regulates cell death by controlling the mitochondrial membrane permeability (PubMed:11368354). Appears to function in a feedback loop system with caspases (PubMed:11368354). Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (PubMed:11368354). Also acts as an inhibitor of autophagy: interacts with BECN1 and AMBRA1 during non-starvation conditions and inhibits their autophagy function (PubMed:18570871, PubMed:21358617, PubMed:20889974). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785). {PubMed:1508712, PubMed:17418785, PubMed:18570871, PubMed:20889974, PubMed:21358617, PubMed:8183370, PubMed:11368354}.